The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy
Open accessAbstract
Amyloid-related imaging abnormalities (ARIA) are adverse events reported in Alzheimer's disease trials of anti-amyloid beta (Aβ) therapies. This review summarizes the existing literature on ARIA, including bapineuzumab, gantenerumab, donanemab, lecanemab, and aducanumab studies, with regard to potential risk factors, detection, and management. The pathophysiology of ARIA is unclear, but it may be related to binding of antibodies to accumulated Aβ in both the cerebral parenchyma and vasculature, resulting in loss of vessel wall integrity and increased leakage into surrounding tissues. Radiographically, ARIA-E is identified as vasogenic edema in the brain parenchyma or sulcal effusions in the leptomeninges/sulci, while ARIA-H is hemosiderin deposits presenting as microhemorrhages or superficial siderosis. ARIA tends to be transient and asymptomatic in most cases, typically occurring early in the course of treatment, with the risk decreasing later in treatment. Limited data are available on continued dosing following radiographic findings of ARIA; hence, in the event of ARIA, treatment should be continued with caution and regular monitoring. Clinical trials have implemented management approaches such as temporary suspension of treatment until symptoms or radiographic signs of ARIA have resolved or permanent discontinuation of treatment. ARIA largely resolves without concomitant treatment, and there are no systematic data on potential treatments for ARIA. Given the availability of an anti-Aβ therapy, ARIA monitoring will now be implemented in routine clinical practice. The simple magnetic resonance imaging sequences used in clinical trials are likely sufficient for effective detection of cases. Increased awareness and education of ARIA among clinicians and radiologists is vital.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 7×
“Higher frequency of ARIA-E among ApoE ε4 carriers has also been observed in clinical studies of gantenerumab, donanemab, lecanemab, and aducanumab (11, 21, 23, 29, 30).”
BackgroundInfluentialTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 5×
“5% of 103 ARIA-E cases in ApoE ε4 carriers were asymptomatic) (31).”
BackgroundInfluentialDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 4×
“Clinical trials of agents that target the N-terminus of Aβ, such as aducanumab, bapineuzumab, or donanemab, have reported incidences of ARIA-E as high as 55% in apolipoprotein E (ApoE) ε4 carriers (10, 24, 29, 31).”
BackgroundResultInfluentialPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 5×
“For example, treatment with solanezumab, which binds to soluble monomeric Aβ, was associated with a lower incidence of ARIA than were other anti-Aβ mAbs that target aggregated forms of Aβ (13).”
BackgroundResultInfluentialCerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 5×
“ARIA-H refers to hemosiderin deposits presenting as microhemorrhages (hemorrhages <10 mm) in the brain parenchyma and/or localized superficial siderosis (located in the subarachnoid space) (Figure 1) (14, 15).”
BackgroundMethodResultInfluentialSwanson, C. J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00813-8 · Cited by 847 · cited 6×
“Higher frequency of ARIA-E among ApoE ε4 carriers has also been observed in clinical studies of gantenerumab, donanemab, lecanemab, and aducanumab (11, 21, 23, 29, 30).”
BackgroundResultInfluential
Cited by
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA · doi:10.1001/jama.2023.13239 · Cited by 2,932
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy
Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., & Bathla, G. (2023) · RadioGraphics · doi:10.1148/rg.230009 · Cited by 90
Villain, N., Planche, V., & Levy, R. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.06.012 · Cited by 87
Zhao, Z., Liu, Y., Ruan, S., & Hu, Y. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s444115 · Cited by 49
“24,25 This may be due to the antibody promoting the disaggregation of amyloid plaques into soluble forms when it binds with them, triggering glial cell-mediated neuroinflammation.”
BackgroundSalloway, S., Pain, A., Lee, E., Papka, M., Ferguson, M. B., Wang, H., Hu, H., Lu, M., Oru, E., Ardayfio, P. A., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70293 · Cited by 37
Jeong, S. Y., Suh, C. H., Kim, S. J., Lemere, C. A., Lim, J.-S., & Lee, J.-H. (2024) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0105 · Cited by 26
Amyloid-lowering monoclonal antibodies for the treatment of early Alzheimer’s disease
Leisher, S., Bohorquez, A., Gay, M., Garcia, V., Jones, R., Baldaranov, D., & Rafii, M. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01021-8 · Cited by 26
Fibrin-targeting immunotherapy for dementia
Kantor, A. B., Akassoglou, K., & Stavenhagen, J. B. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.105 · Cited by 24
New insights into innate immunity in Alzheimer’s disease: From APOE protective variants to therapies
Chen, Y., & Holtzman, D. M. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.08.001 · Cited by 19
Navarro-Gómez, N., Valdes-Gonzalez, M., Garrido-Suárez, B. B., & Garrido, G. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.2 · Cited by 7
“There are two isoforms of this enzyme, α and β. GSK3β is mainly expressed in the CNS (56).”
BackgroundInfluentialFocused ultrasound blood-brain barrier opening: a review of post-procedure MRI outcomes
LeBlang, S., Mehta, R. I., D’haese, P.-F., Grinspan, A., Sokolov, A., & Frazzetta, G. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2737272
Metadata
- Authors
- Barakos, J., Purcell, D., Suhy, J., Chalkias, S., Burkett, P., Grassi, C. M., Castrillo-Viguera, C., Rubino, I., & Vijverberg, E.
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 9
- Issue
- 2
- Pages
- 211-220
- ISSN
- 2274-5807 (ISSN-L)
- OpenAlex
- W4210807180
- Cited by
- 165
- References
- 22
- FWCI
- 15.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.